These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23817320)

  • 1. Profile: ImmunoCellular Therapeutics Ltd.
    Yu JS
    Hum Vaccin Immunother; 2012 Dec; 8(12):1745. PubMed ID: 23817320
    [No Abstract]   [Full Text] [Related]  

  • 2. Ovarian cancer vaccine candidate DPX-Survivac: positive interim results from phase 1.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1743. PubMed ID: 23980265
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy for ovarian cancer: what's next?
    Kandalaft LE; Powell DJ; Singh N; Coukos G
    J Clin Oncol; 2011 Mar; 29(7):925-33. PubMed ID: 21079136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized vaccination against ovarian cancer: what are the possibilities?
    Tanyi JL; George E
    Expert Rev Vaccines; 2018 Nov; 17(11):955-958. PubMed ID: 30362844
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
    Schaller TH; Sampson JH
    Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell vaccines to combat glioblastoma.
    Wheeler CJ
    Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
    [No Abstract]   [Full Text] [Related]  

  • 7. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
    Reardon DA; Mitchell DA
    Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines.
    Grohmann U; Bianchi R; Belladonna ML; Silla S; Surace D; Fioretti MC; Puccetti P
    Adv Exp Med Biol; 1997; 417():579-82. PubMed ID: 9286421
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccine-based clinical trials in ovarian cancer.
    Leffers N; Daemen T; Boezen HM; Melief KJ; Nijman HW
    Expert Rev Vaccines; 2011 Jun; 10(6):775-84. PubMed ID: 21692699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical issues in cancer vaccine trial design.
    Clifton GT; Kohrt HE; Peoples GE
    Vaccine; 2015 Dec; 33(51):7386-7392. PubMed ID: 26392010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on investigational drugs and immunotherapies for glioblastoma.
    Miller JJ; Curry WT; Cahill DP; Dietrich J
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1007-9. PubMed ID: 27415034
    [No Abstract]   [Full Text] [Related]  

  • 12. The contenders. Vaccines and viruses take aim at cancer cells.
    Clancy F
    Minn Med; 2005 Apr; 88(4):24-8. PubMed ID: 15940888
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding dendritic cell immunotherapy in ovarian cancer.
    Drakes ML; Stiff PJ
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune therapy for ovarian cancer: promise and pitfalls.
    Thibodeaux SR; Curiel TJ
    Int Rev Immunol; 2011; 30(2-3):102-19. PubMed ID: 21557637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cell immunotherapy: the right bullet for the right target.
    Ghebeh H; Bakr MM; Dermime S
    Hematol Oncol Stem Cell Ther; 2008; 1(1):1-2. PubMed ID: 20063521
    [No Abstract]   [Full Text] [Related]  

  • 16. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.
    Chiriva-Internati M; Mirandola L; Kast WM; Jenkins MR; Cobos E; Cannon MJ
    Int Rev Immunol; 2011; 30(2-3):71-86. PubMed ID: 21557635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12 as an adjuvant for cancer immunotherapy.
    Rodolfo M; Colombo MP
    Methods; 1999 Sep; 19(1):114-20. PubMed ID: 10525447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two years of Provenge.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Apr; 8(4):505. PubMed ID: 22832253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.